Replies to post #246191 on Avid Bioservices Inc (CDMO)

[asmarterwookie]

So says the all knowing definer of partnerships...funny that AZN referred PPHM as a PARTNER and SK referred to AZN as a partner....AZN supplying product and support is as good as cash...but please...do go on with your stories...

Oh...and can you define what you mean by a breakout and what data would cause that in 6 months? TIA

wook

[cjgaddy]

You said, "The company doesn't even mention partnership discussions anymore." (PPHMVERYLONG 12-19-15 #246187).

On the Dec. 10 2015, Conf.Call PPHM's VP of Business Development, STEVE WORSLEY said,
“We continue our dialog with a number of other world leading pharmaceutical organizations and believe that bavituximab will continue to generate partnering interest. I will now turn the call over to Rob Garnick...”
http://tinyurl.com/jkp885g

[Couch]

I'm glad we agree CJ corrected the misinformation. Clearly management has indeed been discussing partnerships as shown in the sticky note above. That is a fact.

[biopharm]

You have failed 100% in my view. Why would you try to pass off the collaboration/partnership Peregrine Pharmaceuticals has with AstraZeneca as something less than a partnership?

CJ's post below is a must read and explains it all perfectly. This post puts to rest the misinformation.

http://investorshub.advfn.com/boards/manage_msg.asp?message_id=119295823

-----------------------------------------------

It seems you are completely off track in your legacy way of thinking here. If Peregrine would have been required to pay for the cost of the drug ( up to $100k ) per patient in a trial then they would have had to raise that money possibly via an ATM sale, BUT THEY DO NOT HAVE TO NOW, because AstraZeneca is paying 100% of the cost of treatment for all patients.

This is why Peregrine CEO Steven King made reference to how much they are saving in cash.

SK 12-15-15/BioWorld on AZN: “We save probably as much as we're spending because of the cost of these drugs.”

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=119232230

Next, anyone paying attention knows 100% that AstraZeneca would not just volunteer their network and expertise and partnership and just give Peregrine a non-exclusive without a fight.

Peregrine had the leverage in those negotiations...huh? : )

Big Pharma loves to tie up small biotechs with exclusive deals because that is just another tactic to slow down the competition.

Peregrine is not about to slow down.

Bavituximab is in the hands of dozens of collaborators and it is much too late to hold it back now.

Combinations are fast approaching and Bavituximab will have to be included to even have a chance for the most optimal, robust, immune response.

David Berman ex-BMS knows this very well : )